David Fleischer, MD, professor of pediatrics at Children’s Hospital Colorado.

VIASKIN Peanut Patch Shows Strong Desensitization in Phase 3 Trial, With David Fleischer, MD

American Academy of Allergy, Asthma & Immunology (AAAAI)

 annual meeting in Philadelphia highlight the potential of the VIASKIN peanut patch, DBV Technologies’ epicutaneous immunotherapy containing 250 µg of peanut protein (1/1000th of 1 peanut kernel), as a practical, noninvasive option for children with 

. In the phase 3 VITESSE trial, the largest food allergy immunotherapy study to date, 82.8% of children receiving this peanut patch (VP250) increased their eliciting dose over 12 months.

“[With] that increase in eliciting dose, we know it's working,” David Fleischer, MD, professor of pediatrics at Children’s Hospital Colorado and global principal investigator of the VITESSE trial, told 

during the meeting. “Hopefully, it translates into protection from peanut allergic reactions.”

The study, conducted across 87 sites in Australia, Canada, Europe, and the US, sought to assess the efficacy and safety of VP250 in peanut-allergic children aged 4 – 7 years (baseline peanut eliciting dose ≤ 100 mg, psIgE > 0.7 kUA/L, and a skin prick test ≥ 6 mm). Children were randomized to receive either VP250 (n = 438; 60.5% males; mean age, 5.7 years) or placebo (n = 216; 65.7% males; mean age, 5.7 years).

VITESSE met its primary endpoint, with 46.3% of treated children (baseline eliciting dose of ≤ 30 mg) classified as responders compared with 14.7% in the placebo group (

 <.0001). Among children with a baseline eliciting dose of 100 mg, 43.1% were responders versus 14.6% in the placebo group. Beyond that primary outcome, most patients experienced measurable improvement: approximately 82.8% increased their eliciting dose over 12 months (versus 48% on placebo), and 60% improved by ≥ 2 dose levels during food challenge testing (versus 23.4% on placebo).

Unlike oral immunotherapy, which requires strict dosing protocols and activity restrictions, epicutaneous immunotherapy offers a simplified approach. The VIASKIN peanut patch delivers a small, fixed dose of allergen through the skin, without the need for dose escalation, dietary timing considerations, or limitations on exercise or illness.

Fleischer said the ease of use helps with adherence rates, which exceeded 96% in the trial. The safety profile remained favorable, with most treatment-emergent adverse events being mild, localized skin reactions. Serious adverse events were rare, and rates of treatment-related anaphylaxis were low.

Nearly 4 times as many children in the placebo arm experienced a decline in their eliciting dose over the study period compared to the patch arm (24% vs 6.4%). This finding reinforces the natural history of peanut allergy, which rarely resolves spontaneously.

“Only about 20% outgrow peanut allergy, and it shows that patients can get worse in the sense that their reaction threshold can lower over time,” Fleischer said. “It's all the importance in starting these therapies early…If only 1 in 5 outgrow it, we want to definitely try to protect these patients…we may be able to get them to the point where they can eat peanut[s] freely in their diet. That's the ultimate goal with these therapies.”

DBV Technologies has indicated plans to submit a Biologics License Application to the FDA in 2026.

Relevant disclosures for Fleischer include DBV Technologies, ARS Pharmaceuticals; UpToDate, Bryn Pharma, Aquestive Therapeutics, Nasus, and Genentech, and Grow Happy.

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting. DBV Technologies. Published February 28, 2026. Accessed March 20, 2026. 

https://dbv-technologies.com/press_releases/dbv-technologies-highlights-additional-data-from-successful-phase-3-vitesse-study-at-the-aaaai-2026-annual-meeting/

Videos

Phase 3 VITESSE data show VIASKIN peanut patch improves tolerance in most children, with high adherence and a favorable safety profile.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Takeaways on Icotrokinra and FDA approval and Psoriasis for Clinicians, With Linda Stein Gold, MD

Takeaways on Icotrokinra and Psoriasis for Clinicians, With Linda Stein Gold, MD

In the second part of her interview, Linda Stein Gold, MD, of Henry Ford Health System, touched on the gap between what topicals can realistically offer and when systemic therapy should enter the picture, how icotrokinra's oral profile can change the conversation among hesitant patients, and where she hopes the research goes following the 

US Food and Drug Administration (FDA) approval

 editorial team what primary care clinicians should take away about recognizing when a psoriasis patient has outgrown topical therapy, Stein Gold opened with a candid observation about a pattern she sees across the field: treatment inertia.

“We tend to have treatment inertia,” Stein Gold said. “When it comes to our psoriasis patients, we put them on a topical medication. Maybe they're not doing so well, so maybe we think about another topical medication, and we don't always progress to a systemic medication, probably as quickly as we need to first.”

Her message to primary care providers suggests when topical therapy is not delivering meaningful improvement, it may be time to consider a systemic option rather than cycling through more of the same. This framing set up Stein Gold’s response to the second question, which inquired as to how a clinician might reopen the systemic therapy conversation with a patient who has previously declined injectables.

Stein Gold's answer centered on what icotrokinra can provide as an oral agent. She pointed to the nature of psoriasis as a systemic disease driven by systemic inflammation, particularly in those living with moderate to severe plaque involvement, and that treating the whole patient means addressing that underlying pathway rather than managing surface symptoms alone.

Icotrokinra targets the interleukin (IL)-23 receptor, which she described as a key receptor in a pathway now well understood and recognized as central to the pathogenesis of psoriasis. For individuals who have resisted treatment escalation because of a fear of injections, Stein Gold pointed to icotrokinra's once-daily oral dosing on an empty stomach in the morning as removing the primary barrier.

Efficacy begins within the initial few weeks of use and builds through the primary 16-week endpoint and beyond. The trial data, Stein Gold noted, gives her genuine confidence in recommending the drug to systemic candidates across age cohorts. On the question of what she hopes comes next for icotrokinra research, Stein Gold was specific and forward-looking.

She expressed hope for continued investigation into psoriatic arthritis (PsA), described as the natural next step in research on icotrokinra given how central the IL-23 pathway is to both skin and joint disease. She also made a point of flagging the pediatric age gap. While the current FDA approval extends down to age 12, she noted psoriasis does not begin at 12 and describes an oral option for an even younger population as a meaningful advance.

Disclosures: Stein Gold has reported serving as an investigator, advisor, or speaker for AbbVie, Amgen, Arctis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB. AWA has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Arcutis, BMS, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, Galderma, Incyte, Johnson & Johnson, Leo Pharma, Novartis, Parexel, Pfizer, Regeneron, Sanofi, Takeda, and UCB. RB is an advisory board member, consultant, speaker, investigator for, or received honoraria or grants from AbbVie, Alumis, Amgen, AnaptysBio, Arcutis, BMS/Celgene, Eli Lilly, Johnson & Johnson, LEO Pharma, Organon, Nimbus, Takeda, UCB, VentyxBio, Vyne, Xencor, and Zurabio, and is also an employee and shareholder of Innovaderm Research.

Campbell P. Icotrokinra, an Oral Il-23 Inhibitor, Receives FDA Approval for Psoriasis. HCPLive. March 18, 2026. Accessed March 20, 2026. 

https://www.hcplive.com/view/icotrokinra-receives-fda-approval-for-psoriasis

Johnson and Johnson. FDA approves ICOTYDE (icotrokinra), the first and only targeted oral peptide IL-23 receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis. Press release. Published March 18, 2026. Accessed March 20, 2026. 

https://www.jnj.com/media-center/press-releases

After the oral IL-23 inhibitor icotrokinra's (Icotyde) FDA approval, this interview covers what primary care clinicians should conclude.


Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Senior Allergy Dietitian at the Royal Children’s Hospital, Clinician-Scientist Fellow at MCRI & Honorary Senior Research Fellow at Melbourne University,

TreEAT: Clinical Implications, Screening Practices, and Next Steps, With Vicki McWilliam, MND, PhD

View part one of our conversation with McWilliam here.

Routine pre-screening of peanut-allergic infants for tree nut sensitization risks over-calling true allergy — and the TreEAT data offer quantitative support for that concern, with approximately 33% of infants sensitized to tree nuts at baseline yet true clinical allergy rates of just 12.4% (n = 11/89; 95% CI, 6.3–21.0%) in the home introduction arm and 18.9% (n = 18/95; 95% CI, 11.6–28.3%) in the multi-nut OFC arm on food challenge confirmation. Much of the reported ~30% peanut co-allergy rate cited in the tree nut literature, McWilliam suggested, may reflect sensitization rates rather than true allergy — an important distinction with direct implications for how allergists counsel families in clinic.

 2026 Annual Meeting held in Philadelphia, Pennsylvania, from February 27 to March 2, she walked through the practical clinical takeaways from the preliminary TreEAT data and outlined the evidence gaps she most wants to address in follow-up work. On shared decision-making, her core message was that whichever introduction method a family chooses — supervised multi-nut OFC or graded home introduction — the data support that both can be pursued safely. No infant across either arm of the 212-patient single-center trial experienced anaphylaxis, providing a meaningful safety floor for clinicians having these conversations. McWilliam did note an important caveat around generalizability: the study's home introduction success rate likely reflects the heightened support families received as trial participants, and real-world uptake without that scaffolding may look different — consistent with the clinic observation that only about 25% of families were willing to attempt home introduction unprompted prior to the study.

McWilliam also flagged the study's limitations openly: single-center, conducted in Melbourne, and with a primary outcome assessed only at 18 months — a timepoint at which the immune system remains plastic and allergy status may still be in flux. Peanut allergy resolution was observed in 26.3% (n = 25/95; 95% CI, 18.0–36.7%) of the multi-nut OFC arm and 30.3% (n = 27/89; 95% CI, 22.0–42.1%) in the home introduction arm — broadly consistent with the approximately 20% resolution rate reported in the broader literature, and with co-allergy to tree nuts lower than previously reported figures. The unresolved question is whether infants who did not maintain ongoing nut exposure following the intervention have since developed further allergies — something only longer follow-up can answer. McWilliam described active efforts to secure funding for follow-up assessments at ages four and five, where those children now sit, with a full primary outcome paper expected for publication later this year.

“It was really reassuring to know out of those 200 infants that were introducing the tree nuts, either via home introduction or the malting up butter, we're not having anaphylaxis. So that was quite reassuring that whatever method we do with our families, that we've got a fair amount of safety data now to be able to say that this is something we're comfortable to do,” McWilliam said.

McWilliam’s reported disclosures include Nutricia

McWilliam V, Parker K, Koplin J, et al. The TreEat Study: A Randomized Controlled Trial Investigating the Efficacy and Safety of Early Introduction of Tree Nuts for the Prevention of Tree Nut Allergy in Infants with Peanut Allergy. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Abstract #L15

A clip from the inaugural episode of ABCs in Dermatology exploring what drew our hosts to dermatology

ABCs in Dermatology: Our Hosts' Journeys to Dermatology

 introduces co-hosts Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, through a discussion that reflects the diverse pathways that ultimately lead clinicians into the field. In the opening conversation, both hosts share how early academic exposure, clinical experiences, and mentorship shaped their decisions to pursue dermatology, offering insight into the intellectual and human elements that define the specialty.

Bunick describes how his background in molecular research, specifically in nucleotide excision repair and the role of the XPC protein in DNA damage, first connected him to dermatology through its relevance to skin cancer biology. Although his initial impressions of the field were not favorable, a later clinical rotation and the influence of a mentor specializing in cutaneous T-cell lymphoma reframed his perspective, highlighting the combination of scientific depth and patient impact that dermatology offers.

Ackerman’s path similarly began with early research exposure, working in a cutaneous oncology clinic studying melanoma susceptibility during her undergraduate years. Her experience in medical school further broadened her perspective, as she explored multiple specialties before recognizing dermatology’s ability to integrate elements of internal medicine, surgery, and longitudinal patient care. She emphasizes the specialty’s unique capacity to address a wide spectrum of disease while maintaining a strong connection with patients through visible and tangible manifestations of illness.

Together, their discussion underscores the role of mentorship, clinical exposure, and interdisciplinary interest in shaping careers in dermatology, while also highlighting the field’s balance of complexity, procedural skill, and patient-centered care.

Relevant disclosures for Bunick include AbbVie, South Beach Symposium, Almirall, Apogee Therapeutics, Arcutis Biotherapeutics, Daiichi Sankyo, Eli Lilly, LEO Pharma, US, Novan, Novartis, Ortho Dermatologics, Palvella Therapeutics, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Timber Pharmaceuticals, and UCB. Relevant disclosures for Ackerman include AbbVie, Alumis, Amgen, Arcutis, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, L'Oréal, Novartis, Sun Pharmaceutical, and UCB.

Hosts reveal how research, mentors, and clinic rotations spark a passion for skin disease and what makes dermatology unique.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Dr. Deepak Bhatt highlights 4 trials to watch in the late-breaking sessions at ACC.26.

ACC.26 Late-Breakers to Watch, With Deepak Bhatt, MD, MPH, MBA

As the cardiovascular community prepares to convene in New Orleans for the 

American College of Cardiology’s Annual Scientific Session & Expo (ACC.26)

, attention is once again turning to the late-breaking clinical trials expected to define the meeting’s scientific and clinical impact.

Each year, these presentations serve as a bellwether for where cardiovascular care is headed, often introducing data directly informs guideline updates, reshapes treatment algorithms, and accelerates adoption of emerging therapies across practice settings.

The momentum heading into ACC.26 follows a high-impact showing at ACC.25, where more than 50 late-breaking trials highlighted rapid advances across cardiometabolic care, lipid management, and interventional cardiology.

Notable data included the REVERSE-IT trial demonstrating rapid reversal of ticagrelor’s antiplatelet effects, the ALPACA study showing profound and sustained reductions in lipoprotein(a), and the ADVANCE-HTN trial evaluating novel approaches for treatment-resistant hypertension. These findings underscored a broader shift toward precision therapeutics, long-acting agents, and targeted mechanisms addressing previously unmet clinical needs.

Against this backdrop of accelerating innovation, ACC.26 is expected to build on these themes, with new data poised to further refine risk stratification, expand minimally invasive treatment strategies, and uncover novel drivers of cardiovascular disease. Increasingly, the field is moving toward earlier intervention and more individualized care, supported by advances in both pharmacologic and device-based therapies.

Presentation Title: Prevalence of Endogenous Hypercortisolism in Resistant Hypertension: Results of the MOMENTUM Trial
Presenter: Deepak L. Bhatt, MD, MPH, MBA
NCT06829537

MOMENTUM (NCT06829537), a prospective, multicenter observational study enrolling 1000 patients across 45 US sites, examines whether endogenous hypercortisolism (Cushing's syndrome) underlies treatment resistance in this population. Patients screening positive by dexamethasone suppression test (DST ≥1.8 µg/dL) undergo additional workup and adrenal imaging.

The design mirrors the CATALYST study, which found hypercortisolism in approximately 1 in 4 patients with difficult-to-control type 2 diabetes. Bhatt, a lead investigator and steering committee member, anticipates results will open new therapeutic pathways, potentially including cortisol-modulating agents, for patients whose hypertension remains poorly controlled on standard care.

2. HI-PEITHO (Boston Scientific / PERT Consortium)

Presentation Title: Higher-Risk Pulmonary Embolism Thrombolysis (HI-PEITHO): Primary Results
Presenter: Stavros Konstantinidis, MD, PhD
NCT04790370

HI-PEITHO is the first large-scale randomized controlled trial powered to determine whether ultrasound-facilitated, catheter-directed thrombolysis (USCDT) via the EKOS™ endovascular system plus anticoagulation improves outcomes versus anticoagulation alone in acute intermediate-high-risk pulmonary embolism (PE).

The 7-day primary composite endpoint includes PE-related death, cardiorespiratory decompensation or collapse, and non-fatal symptomatic PE recurrence. Enrolling 544 patients across 72 US and European hospitals, the adaptive-design trial addresses the longstanding gap left by the original PEITHO study, which demonstrated hemodynamic benefit of systemic thrombolysis at the cost of unacceptable hemorrhagic stroke rates. HI-PEITHO employs the validated National Early Warning Score (NEWS ≥9) to standardize decompensation criteria.

3. SURVIV Trial (Instituto Dante Pazzanese de Cardiologia, São Paulo)

Transcatheter Valve-in-Valve Versus Redo-Surgical Valve Replacement for Mitral Bioprosthetic Valve Dysfunction: Primary Results of the SURVIV Randomised Trial
Presenter: Dimytri A. Siqueira, MD, PhD

Bioprosthetic mitral valves inevitably undergo structural deterioration, yet the optimal reintervention strategy, transcatheter mitral valve-in-valve (mViV) via transseptal, balloon-expandable approach versus redo surgical mitral valve replacement (rMVR), has never been tested in a randomized trial.

SURVIV is a prospective, multicenter, open-label RCT enrolling 150 patients with mitral bioprosthetic valve dysfunction across multiple Brazilian centers, randomized 1:1 to mViV or rMVR. Bhatt, a co-investigator, noted the study could shift decision-making away from high-risk redo surgery toward a less invasive standard of care for this growing patient population, particularly as the prevalence of failed bioprostheses rises with longer patient lifespans and expanding valve repair programs.

4. IVUS-CHIP Trial (ECRI / Boston Scientific)

Presentation Title: Intravascular Ultrasound Guidance for Complex High-Risk Indicated Procedures: Primary Results of the IVUS-CHIP Trial
Presenter: Roberto Diletti, PhD
NCT04854070

Despite accumulating evidence favoring intravascular ultrasound (IVUS) guidance over angiography alone in PCI, rigorous randomized data in patients specifically defined as complex and high-risk, the CHIP population, have remained limited.

IVUS-CHIP is a randomized, controlled, multicenter, post-marketing study enrolling 2,020 patients with complex coronary lesions across approximately 40 hospitals in 7 European countries, randomized 1:1 to IVUS-guided versus angiography-guided PCI with a minimum 2-year follow-up. The primary endpoint is target-lesion failure, which is defined as a composite of cardiac death, target-vessel MI, and clinically indicated target-lesion revascularization.

Editor’s Note: Bhatt reports disclosures with GSK, Merck, Cereno Scientific, Angiowave, Boehringer Ingelheim, Novo Nordisk, and others.

Bhatt DL. Key clinical trial insights from ACC 2025, with Deepak Bhatt, MD, MPH, MBA. 

. Published April 9, 2025. Accessed March 20, 2026. 

https://www.hcplive.com/view/key-clinical-trial-insights-from-acc-2025-with-deepak-bhatt-md-mph-mba-

Corcept Therapeutics. Corcept Therapeutics initiates MOMENTUM trial to determine prevalence of hypercortisolism in patients with resistant hypertension. 

. Published March 10, 2025. Accessed March 19, 2026. 

https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-initiates-momentum-trial-determine/

Skhirtladze-Dworschak K, Konstantinidis SV, Rosenfeld K, et al. Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: rationale and design of the HI-PEITHO study. 

. 2026;S0002870326000013. doi:10.1016/j.ahj.2026.01.001. Accessed March 19, 2026.

Boston Scientific Corporation. The HI-PEITHO study. Boston Scientific website. Accessed March 19, 2026. 

https://www.bostonscientific.com/en-EU/medical-specialties/vascular-surgery/venous-thromboembolism-portal/pulmonary-embolism/clinical-data/hi-peitho.html

Siqueira DA, Abizaid AAC, Ramos AA, et al. Transcatheter valve-in-valve versus redo-surgical valve replacement for mitral bioprosthetic valve dysfunction: rationale and design of the SURVIV randomized trial. 

. Published online 2026. doi:10.4244/EIJ-D-25-01090. Accessed March 19, 2026.

Deepak Bhatt, MD, MPH, MBA, discusses 4 trials to watch at the upcoming ACC.26.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Balázs Szigeti, PhD, from the Translational Psychedelic Research Program at University of California San Francisco (UCSF)

Findings suggest psychedelics match antidepressants for symptom relief, with future research needed on real-world use and functional outcomes.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Psychedelics Expand Options, Not Efficacy, in Depression Care, With Balázs Szigeti, PhD

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Articles

GLP-1 discontinuation increases major adverse cardiovascular event risk in type 2 diabetes, highlighting the need for continuous therapy to sustain cardiometabolic benefit.

Atherosclerotic Cardiovascular Disease

GLP-1 Discontinuation Tied to Loss of Cardiovascular Protection  

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Clinicians compare newest asthma/COPD biologics, highlighting dupilumab’s edge, biomarker shifts, and insurance barriers shaping real-world use.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD Biologics in Practice: Exacerbation Reduction is No Longer Enough

Linda Stein Gold, MD, shares her perspective on the clinical significance of icotrokinra's FDA approval and what dermatologists need to know.

Key Points on Icotrokinra Following FDA Approval for Psoriasis, With Linda Stein Gold, MD

Experts discuss which outcome instruments are most useful in routine clinical practice and address how patients' tendency to underreport disease burden before experiencing effective treatment affects baseline severity assessment and escalation decision-making.

Video Series

Special Reports

Outcome Instruments in Practice and Baseline Underreporting in Untreated CSU

FDA clears setmelanotide for acquired hypothalamic obesity for ages 4 years and older, delivering 15.8% BMI drop in TRANSCEND.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

FDA News

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

FDA Approves Setmelanotide (Imcivree) for Acquired Hypothalmic Obesity

Experts review a phase 2 exploratory analysis of barzolvolimab in CSU, examining off-treatment efficacy at 28 weeks after the final dose, complete response rates, and quality-of-life outcomes among patients who achieved well-controlled disease after 52 weeks of treatment.

Barzolvolimab Post-Treatment Durability —Off-Treatment Data, Complete Response Rates, and Quality-of-Life Outcomes

Experts review REMIX-1/-2 pooled data on daily Urticaria Activity Score through day 7 and UCT progression through week 52, examining what daily resolution adds to the understanding of BTK inhibition onset and how the trajectory of disease control informs follow-up conversations with patients.

New Remibrutinib Data — Daily Disease Activity, Severity Band Shifts, and UCT Trajectory Through Week 52

Learn how FIT, Cologuard, blood tests and colonoscopy compare on accuracy, follow-up timing, and easier prep options for screening.

Overcoming Barriers and Advancing Precision in Colorectal Cancer Screening 

Experts discuss the most clinically meaningful changes in the 2026 international urticaria guideline update, including the expanded step-up therapy framework and the current limitations of biomarkers in routine CSU practice.

Latest News

VIASKIN Peanut Patch Shows Strong Desensitization in Phase 3 Trial, With David Fleischer, MD

Takeaways on Icotrokinra and Psoriasis for Clinicians, With Linda Stein Gold, MD

TreEAT: Clinical Implications, Screening Practices, and Next Steps, With Vicki McWilliam, MND, PhD

ABCs in Dermatology: Our Hosts' Journeys to Dermatology

ACC.26 Late-Breakers to Watch, With Deepak Bhatt, MD, MPH, MBA